Article

The North Jutland County Diabetic Retinopathy Study: population characteristics.

Department of Ophthalmology, Aalborg Sygehus South, Aarhus University Hospital, Hobrovej 18-22, Aalborg DK-9100, Denmark.
British Journal of Ophthalmology (impact factor: 2.9). 12/2006; 90(11):1404-9. DOI:10.1136/bjo.2006.093393 pp.1404-9
Source: PubMed

ABSTRACT Several population-based studies have reported blood glucose levels and blood pressure to be risk factors for the development of diabetic retinopathy. These studies were initiated more than two decades ago and may therefore reflect the treatment and population composition of a previous era, suggesting new studies of the present population with diabetes. Aim and methods: This cross-section study included 656 people with type 1 diabetes and 328 with type 2 diabetes. Crude prevalence rates of proliferative diabetic retinopathy, clinically significant macular oedema and several specific retinal lesions were assessed, together with their association to a simplified and internationally approved retinal grading.
The point prevalence of proliferative retinopathy was found to be 0.8% and 0.3% for type 1 and type 2 diabetes. Equivalent prevalence rates of clinically significant macular oedema were 7.9% and 12.8%, respectively. The most frequently occurring retinal manifestations increased in number until retinopathy level 3, and then decreased.
The point prevalence of proliferative retinopathy is lower than that found in previous studies, whereas it is increased for clinically significant macular oedema. These data suggest different risk factors for these clinical entities.

0 0
 · 
0 Bookmarks
 · 
13 Views
  • Source
    Article: Diabetic retinopathy: treatment and prevention.
    Paul M Dodson
    [show abstract] [hide abstract]
    ABSTRACT: Diabetic eye disease is the major cause of blindness and vision loss among working-age people in developed countries. Microangiopathy and capillary occlusion underlie the pathogenesis of disease. While laser treatment is regarded as the standard therapy, intensive medical management of glycaemia and hypertension is also a priority in order to reduce the risk of diabetic retinopathy. Recent data have prompted a re-evaluation of the role of lipid-modifying therapy in reducing diabetic retinopathy. The Fenofibrate Intervention for Event Lowering in Diabetes (FIELD) study demonstrated a significant 30% relative reduction in the need for first retinal laser therapy in patients with (predominantly early-stage) type 2 diabetes treated with fenofibrate 200 mg daily, from 5.2% with placebo to 3.6% with fenofibrate, p=0.0003. The benefit of fenofibrate was evident within the first year of treatment. These promising data justify further evaluation of the mechanism and role of fenofibrate, in addition to standard therapy, in the management of diabetic retinopathy.
    Diabetes & Vascular Disease Research 10/2007; 4 Suppl 3:S9-S11. · 2.12 Impact Factor
  • Source
    Article: Burden of illness of diabetic macular edema: literature review.
    Er Chen, Mark Looman, Marianne Laouri, Meghan Gallagher, Karen Van Nuys, Darius Lakdawalla, Joan Fortuny
    [show abstract] [hide abstract]
    ABSTRACT: To provide an overview of the literature on the burden of diabetic macular edema (DME) in the United States and selected European countries. Computerized searches of English-language literature were conducted in PubMed/MEDLINE (1980-2009). The searches were supplemented with electronic and manual searches of relevant society/association proceedings and bibliographies of electronically identified sources. Abstracts were reviewed for relevance to any of the following topics: epidemiology, including prevalence and incidence; health outcomes; resource use and treatment patterns; and economic and humanistic burden associated with DME. Relevant full text articles were retrieved and major findings were synthesized and compared within and across countries. A total of 400 citations were included in the initial review. After abstract screening, 47 articles were deemed pertinent and summarized in this review. The prevalence of DME among diabetic patients ranged from 0.85% to 12.3% across the countries studied. The prevalence and incidence of DME vary depending on type of diabetes (1 vs. 2), insulin- vs. non-insulin-dependence, and duration of disease (years since diagnosis). Although literature findings are limited and indicate a need for further investigation, a synthesis of the available results indicates that DME has a negative impact on patients' health-related quality of life. In addition, patients with DME consume significantly more healthcare resources and incur higher costs compared to diabetic patients without retinal complications. There remains a need for consistent data capture and assessment within and between countries included in this analysis. Despite the limited evidence, DME appears to be a costly disease that has a negative impact on patients' quality of life.
    Current Medical Research and Opinion 07/2010; 26(7):1587-97. · 2.38 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

blood glucose levels
 
blood pressure
 
clinical entities
 
clinically significant macular oedema
 
Crude prevalence rates
 
diabetes
 
diabetic retinopathy
 
Equivalent prevalence rates
 
point prevalence
 
population-based studies
 
previous era
 
proliferative diabetic retinopathy
 
proliferative retinopathy
 
retinal grading
 
retinal manifestations
 
retinopathy level 3
 
specific retinal lesions
 
type 1 diabetes
 
type 2 diabetes
 

L L Knudsen